WASHINGTON, April 16 (Bloomberg News) â€” Glaxo- SmithKline P.L.C. has won the
Food and Drug Administration’s approval to market its antidepressant Paxil
for treating general anxiety disorder, a new use for the drug.
That makes Paxil the first drug in its class to be approved for the
condition, which affects about 10 million Americans and involves excessive,
often debilitating worrying, the company said today.
136 total views, no views today